Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

迈威生物 (688062.SH)，一家全产业链布局的创新型生物制药公司， 宣布将于当地时间 2025 年 4 月 25-30 日在美国芝加哥举行的 2025 年美国癌症研究协会 (AACR) 年会，以壁报形式公布 6 项研究成果 。

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor ... extensive expertise in drug discovery, Laekna ...